U.S. Consumer Advocate Urges U.S. Inspection Of Shanghai Hualian Plants
This article was originally published in PharmAsia News
Executive Summary
A U.S. consumer advocate says the U.S. FDA should inspect immediately all the plants of China's Shanghai Hualian drug maker in the wake of last year's scandal at one of its plants. Two officials of Shanghai Hualian, a division of Shanghai Pharmaceutical Group, were detained by Shanghai police during an investigation after nearly 200 cancer patients were harmed by Hualian leukemia drugs made at one of the division's plants that also produces mifepristone. The drug ingredient is the primary ingredient in the abortion drug RU-486. The division is the sole supplier of the controversial abortion drug, but a Shanghai regulator said the leukemia and RU-486 drugs were made at two different plants. Danco Laboratories has U.S. clearance for the drug as Mifeprex. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.